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1. Introduction 
Cancer is one of the leading cause of death worldwide.1 In 2010, a total of 1,529,560 new 
cancer cases and 569,490 cancer deaths were estimated in the United States alone.1 
Despite advances in our understanding of tumor biology, cancer biomarkers, surgical 
procedures, radio- and chemotherapy, the overall survival rate from cancer has not 
improved significantly in the past two decades. Early detection, pathological 
characterization, and individualized treatments are recognized as important aspects for 
improving the survival of cancer patients. Many novel approaches, such as imaging for the 
early detection of molecular events in tumors, comprehensive and personalized treatments, 
and targeted delivery of therapeutic agents to tumor sites, have been developed by various 
research groups; and some of these are already in clinical trials or applications for cancer 
patients. Radiation therapy, in conjunction with chemotherapy and surgery, is an effective 
cancer treatment option, especially for radiation-sensitive tumors. Radiation therapy utilizes 
high dose ionizing radiation to kill cancer cells and prevent progression and recurrence of 
the tumor. Traditionally, radiation therapies fall into one of three categories: external 
radiation, internal radiation and systemic radiation therapy. External radiation therapy 
delivers high-energy x-rays or electron or proton beams to a tumor from outside the body, 
often under imaging guidance. Internal radiation therapy (also called brachytherapy) places 
radiation sources within or near the tumor using minimally invasive procedures. Systemic 
radiation therapy delivers soluble radioactive substances, either by ingestion, catheter 
infusion, or intravenous administration of tumor-targeting carriers, such as antibodies or 
biocompatible materials, which carry selected radioisotopes. Although systemic radiation 
offers desirable advantages of improved efficacy as well as potentially reducing radiation 
dosage and side effects, in vivo delivery of radioisotopes with tumor targeted specificity 
needs to address many challenges that include: (i) the selection of radioisotopes with a 
proper half life; (ii) a delivery vehicle that can carry an optimal amount of radioisotopes and 
has favorable pharmacokinetics; (iii) suitable tumor biomarkers that can be used to direct 
the delivery vehicle into cancer cells; and (iv) specific tumor targeting ligands that are 
inexpensive to produce and can be readily conjugated to the delivery vehicles. In addition, a 
multifunctional carrier that not only delivers radioisotopes but also provides imaging 
capability for tracking and quantifying radioisotopes that have accumulated in the tumor is 
highly desirable.2 
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Recent advances in nanotechnology have led to the development of novel nanomaterials 
and integrated nanodevices for cancer detection and screening, in vivo molecular and 
cellular imaging,3 and the delivery of therapeutics such as cancer cell killing radio-
isotopes.4,5 An increasing number of studies have shown that the selective delivery of 
therapeutic agents into a tumor mass using nanoparticle platforms may improve the 
bioavailability of cytotoxic agents and minimize toxicity to normal tissues.6–8 Radiolabelled 
nanoparticles represent a new class of agents which has enormous potential for clinical 
applications. This book chapter provides deep insight into designing  radiolabeled 
nanocarriers or nanoparticles tagged with appropriate radionuclides for cancer diagnosis 
and therapy. The combination of newer nuclear imaging techniques providing high 
sensitivity and spatial resolution such as dual modality imaging with positron emission 
tomography/computed tomography (PET/CT) and use of nanoscale devices to carry 
diagnostic and therapeutic radionuclides with high target specificity can enable more 
accurate detection, staging and therapy planning of cancer. 
2. Molecular imaging with radiolabeled nanoparticles 
The visualization, characterization and measurement of biological processes at the 
molecular and cellular levels in humans and other living systems is termed as molecular 
imaging.9 Molecular imaging includes molecular magnetic resonance imaging (mMRI), 
magnetic resonance spectroscopy (MRS), optical bioluminescence, optical fluorescence, 
targeted ultrasound, single photon emission computed tomography (SPECT) and positron 
emission tomography (PET).10 The availability of scanners for small animals provide similar 
vivo imaging capability in mice, primates and humans. This facilitates correlation of 
molecular measurements between species.11,12 Molecular imaging gives whole body readout 
in an intact system which is more relevant and reliable than in vitro/ ex vivo assays.13 Non-
invasive detection of various molecular markers of diseases lead to earlier diagnosis, earlier 
treatment and better prognosis. Radionuclide-based imaging includes SPECT and PET, 
where internal radiation is administered through a low mass amount of pharmaceutical 
labeled with a radioisotope. The major advantages of radionuclide-based molecular imaging 
techniques (SPECT and PET) over other modalities (optical and MRI) are that they are very 
sensitive, quantitative without any tissue penetration limit.10,15But the resolution of SPECT 
or PET is same as that of MRI. Mostly, nanoparticles are labeled with a radionuclide for non-
invasive evaluation of its biodistribution, pharmacokinetic properties and/or tumor 
targeting efficacy with SPECT or PET.16 
Radioisotopes used for SPECT imaging include 99mTc (t1/2: 6.0 h), 111In (t1/2: 2.8 days) and 
radioiodine (131I, t1/2: 8.0 days). The source of SPECT images are gamma ray emissions. The 
radioisotope decays and emits gamma rays, which can be detected by a gamma camera to 
obtain 3-D images.17,18 The pharmacokinetics, tumor uptake and therapeutic efficacy of an 
111In-labeled, chimeric L6 (ChL6) monoclonal antibody linked iron oxide (IO) nanoparticle 
was studied in athymic mice bearing human breast cancer tumors.19 The 111In-labeled ChL6 
was conjugated to the carboxylated polyethylene glycol (PEG) on dextran-coated IO 
nanoparticles (~ 20 nm in diameter), with one to two ChL6 antibodies per nanoparticle. It 
was proposed that the nanoparticles remained in the circulation for long period of time 
which provides them the opportunity to access the cancer cells. Inductively heating the 
nanoparticle by externally applied alternating magnetic field (AMF) caused tumor necrosis 
at 24 h after AMF therapy. In a follow-up study, different doses of AMF was delivered at 72 
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h after nanoparticle injection.20SPECT imaging was carried out to quantify the nanoparticle 
uptake in the tumor, which was about 14 percentage injected dose per gram (%ID/g) at 48 h 
post-injection. A delay in tumor growth occurred after the AMF treatment, which was 
statistically significant when compared with the untreated group. Subsequently, similar 
nanoparticles with diameters of 30 and 100 nm were also studied.21 Although the heating 
capacity of these large nanoparticles is several times greater, the tumor targeting efficacy 
was significantly less than that of the 20 nm-sized counterparts. In another report, 
recombinant antibody fragments were tested for tumor targeting of these nanoparticles. 
Pharmacokinetic and whole-body autoradiography studies demonstrated that only 5% of 
the injected dose was targeted to the tumor after 24 h.22 
As cancer cells undergo metastasis ie. they invade and migrate to a new tissue. They 
penetrate and attach to the target tissue's basal matrix. This allows the cancer cell to pull 
itself forward into the tissue. The attachment is mediated by cell-surface receptors known as 
integrins, which bind to components of the extracellular matrix. Integrins are crucial for cell 
invasion and migration, not only for physically tethering cells to the matrix, but also for 
sending and receiving molecular signals that regulate these processes.23 Till date 24 integrins 
have been discovered, integrin ǂvǃ3 is the most intensively studied.24,25 It is expressed in 
many types of tumor and plays a critical role in tumor angiogenesis.26 Integrin ǂvǃ3-targeted 
111In-labeled perfluorocarbon (PFC) nanoparticles were tested for the detection of tumor 
angiogenesis in New Zealand white rabbits. The PFC nanoparticles bearing approximately 
10 111In per particle was found to have better tumor-to-muscle ratio than those containing 
approximately 1 111In per particle. At 18 h post-injection, the mean tumor radioactivity in 
rabbits receiving integrin ǂvǃ3-targeted PFC nanoparticle was about 4-fold higher than the 
non-targeted control. Biodistribution studies revealed that nanoparticles were principally 
cleared from spleen.27 Carbon nanotubes are promising carriers for use in biomedical and 
pharmaceutical sciences. Wang et al.(2004) studied its biological properties in vivo.28 They 
labeled water-soluble hydroxylated carbon single-wall nanotubes with radioactive 125In 
atoms, and then the tracer was used to study the distribution of hydroxylated carbon single-
wall nanotubes in mice. They moved easily among the compartments and tissues of the 
body, behaving as small active molecules though their apparent mean molecular weight is 
tremendously large. This study gave a quantitative analysis of carbon nanotubes 
accumulated in animal tissues. Singh et al.(2006) functionalized water-soluble SWNTs with 
the chelating molecule diethylentriaminepentaacetic (DTPA) and labeled them with 111In for 
imaging purposes.29 Both the studies suggested that SWNTs were not retained in any of the 
RES organs (e.g. liver or spleen) and were cleared rapidly from the circulation through the 
renal route. Villa et al. (2008) synthesized and studied the biodistribution of oligonucleotide 
functionalized tumor targetable carbon nanotubes.30 Recently Mehmet Toner have 
developed a microfluidic device composed of carbon nanotubes which can detect cancer 
cells in 1ml of patient’s blood.31 
SPECT and PET are extremely valuable technologies in nuclear medicine. SPECT has 
superior spatial resolution, it can potentially allow for simultaneous imaging of multiple 
radionuclides, since the gamma rays emitted from different radioisotopes can be 
differentiated based on energy.32,33 PET on the other hand has much higher detection 
efficiency.34 The biodistribution of 64Cu (t1/2: 12.7 h)-labeled SWNTs in mice has been 
investigated by PET imaging and Raman spectroscopy. It was found that these SWNTs are 
highly stable in vivo. PEGylated SWNTs exhibit relatively long circulation half-life (about 2 
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h) and low uptake by the RES. Most importantly, efficient targeting of integrin ǂvǃ3-positive 
tumor in mice was achieved with SWNTs coated with PEG chains linked to cyclic RGD 
peptides. Good agreement of biodistribution data obtained by PET and ex vivo Raman 
measurements confirmed the in vivo stability and tumor-targeting efficacy of SWNT-RGD. 35 
Molecular imaging of living subjects continues to rapidly evolve with bioluminescence and 
fluorescence strategies, in particular being frequently used for small-animal models. Keren 
et al.(2008) demonstrated noninvasive molecular imaging of small living subjects using 
Raman spectroscopy. Surface-enhanced Raman scattering nanoparticles and single-wall 
carbon nanotubes were used to demonstrate whole-body Raman imaging, nanoparticle 
pharmacokinetics, multiplexing, and in vivo tumor targeting, using an imaging system 
adapted for small-animal Raman imaging. This imaging modality holds significant potential 
as a strategy for biomedical imaging of living subjects.36 An optimized noninvasive Raman 
microscope was used to evaluate tumor targeting and localization of single walled carbon 
nanotubes (SWNTs) in mice. Raman images were acquired in two groups of tumor-bearing 
mice. The control group received plain-SWNTs, whereas the experimental group received 
tumor targeting RGD-SWNTs intravenously. Raman imaging commenced over the next 72 h 
and revealed increased accumulation of RGD-SWNTs in tumor (p < 0.05) as opposed to 
plain-SWNTs. These results support the development of a new preclinical Raman 
imager.37Photoacoustic imaging of living subjects offers higher spatial resolution and allows 
deeper tissues to be imaged compared with most optical imaging techniques. Many diseases 
do not exhibit a natural photoacoustic contrast, especially in their early stages, so it is 
necessary to administer a photoacoustic contrast agent. De la Zerda et al (2008)  showed that 
single-walled carbon nanotubes conjugated with cyclic Arg-Gly-Asp (RGD) peptides can be 
used as a contrast agent for photoacoustic imaging of tumours. Intravenous administration 
of these targeted nanotubes to mice bearing tumours showed eight times greater 
photoacoustic signal in the tumour than mice injected with non-targeted nanotubes. These 
results were verified ex vivo using Raman microscopy. Photoacoustic imaging of targeted 
single-walled carbon nanotubes may contribute to non-invasive cancer imaging and 
monitoring of nanotherapeutics in living subjects.38 
Carbon nanotubes are promising new materials for molecular delivery in biological systems. 
The long-term fate of nanotubes intravenously injected into animals in vivo is currently 
unknown, an issue critical to potential clinical applications of these materials. Liu et al (2008) 
using the intrinsic Raman spectroscopic signatures of single-walled carbon nanotubes 
(SWNTs), measured the blood circulation of intravenously injected SWNTs and detected 
SWNTs in various organs and tissues of mice ex vivo over a period of three months. 
Functionalization of SWNTs by branched polyethylene-glycol (PEG) chains was developed, 
to prolong SWNT residence time in blood up to 1 day, relatively low uptake in the 
reticuloendothelial system (RES), and near-complete clearance from the main organs in 
approximately 2 months. Raman spectroscopy detected SWNT in the intestine, feces, 
kidney, and bladder of mice, suggesting excretion and clearance of SWNTs from mice via 
the biliary and renal pathways. No toxic side effect of SWNTs to mice was observed in 
necropsy, histology, and blood chemistry measurements. These findings pave the way to 
future biomedical applications of carbon nanotubes.39Liu et al. (2008) further conjugated 
paclitaxel to branched polyethylene glycol chains on SWNTs via a cleavable ester bond to 
obtain a water-soluble SWNT-PTX conjugate. SWNT-PTX affords higher efficacy in 
suppressing tumor growth than clinical Taxol in a murine 4T1 breast cancer model, owing to 
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prolonged blood circulation and 10-fold higher tumor PTX uptake by SWNT delivery likely 
through enhanced permeability and retention. Drug molecules carried into the 
reticuloendothelial system are released from SWNTs and excreted via biliary pathway 
without causing obvious toxic effects to normal organs. Thus, nanotube drug delivery is 
promising for high treatment efficacy and minimum side effects for future cancer therapy 
with low drug doses.40 Selective tumor targeting with a soluble, nanoscale SWNT construct 
mediated by appended specific antibodies was also achieved. The soluble, reactive SWNT 
platform was used as the starting point to build multifunctional constructs with appended 
antibody, metal-ion chelate, and fluorescent chromophore moieties to effect specific 
targeting, to carry and deliver a radiometal-ion, and to report location, respectively.41These 
constructs were found to be specifically reactive with the human cancer cells they were 
designed to target, both in vitro and in vivo. In a follow-up study, PET imaging was carried 
out to determine the tissue biodistribution and pharmacokinetics of 86Y (t1/2: 14.7 h)-labeled 
SWNTs in a mouse model. It was found that 86Y cleared from the blood within 3 hours and 
distributed predominantly to the kidneys, liver, spleen, and bone. Although the activity that 
accumulated in the kidney cleared with time, the whole-body clearance was quite slow.42 
Most of the molecular imaging modalities detect nanoparticle only, whereas radionuclide-
based imaging detects the radiolabel rather than the nanoparticle. The nanoparticle 
distribution is measured indirectly by assessing the localization of the radionuclide, which 
can provide quantitative measurement of the tumor targeting efficacy and pharmacokinetics 
only if the radiolabel on the nanoparticle is stable enough under physiological conditions. 
However, dissociation of the radionuclide (usually metal) from the chelator, and/or the 
radionuclide-containing polymer coating from the nanoparticle, may occur which can cause 
significant difference between the nanoparticle distribution and the radionuclide 
distribution. Thus, the biodistribution data of radiolabeled nanoparticles based on 
PET/SPECT imaging should always be interpreted with caution.7 
No single molecular imaging modality is perfect and sufficient to obtain all the necessary 
information for a particular study.2 For example, it is difficult to accurately quantify 
fluorescence signal in living subjects, particularly in deep tissues; MRI has high resolution 
yet it suffers from low sensitivity; Radionuclide-based imaging techniques have very high 
sensitivity but they have relatively poor resolution. So, combination of  molecular imaging 
modalities can offer synergistic advantages over any modality alone. Multimodality 
imaging using a small molecule-based probe is very challenging due to the limited number 
of attachment points and the potential interference with its receptor binding affinity. For this 
nanoparticles can be investigated as they have large surface areas where multiple functional 
moieties can be incorporated for multimodality molecular imaging.7  
Quantum dots (QDs) are inorganic fluorescent semiconductor nanoparticles with many 
desirable optical properties for imaging applications, such as high quantum yields, high 
molar extinction coefficients, strong resistance to photobleaching and chemical degradation, 
continuous absorption spectra spanning the ultraviolet (UV) to near-infrared (NIR, 700–
900nm) range, narrow emission spectra, and large effective Stokes shifts.41-43 However, in 
vivo targeting and imaging of QDs is very challenging due to the relatively large overall size 
(typically > 20 nm in hydrodynamic diameter) and short circulation half-lives of most QD 
conjugates.41-44Radioactive cadmium telluride/zinc sulfide (Cd125mTe/ZnS) nanoparticles 
were targeted to mouse lung with antibody to mouse lung endothelium and quantified 
using radiological histology in order to test the in vivo targeting efficacy of a nanoparticle–
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antibody (NP–mAb) system. The nanoparticles were linked to either a monoclonal antibody 
to mouse lung thrombomodulin (mAb 201B) or a control antibody (mAb 33), and injected 
into groups of 6-week-old Balb/C female mice. Animals were sacrificed at 1, 4, 24, 72 and 
144 h post-injection, and biodistribution in major organs was determined. Full body 
microSPECT/CT imaging was performed on a pair of mice (experimental and control) 
providing visual confirmation of the biodistribution. The Cd125mTe/ZnS NPs conjugated to 
mAb 201B principally target the lungs while the nanoparticles coupled to mAb 33 
accumulate in the liver and spleen. These data provide, for the first time, a quantitative 
measurement of the in vivo targeting efficacy of an inorganic nanoparticle–mAb system.45 In 
a follow-up study it was found that CdTe NP, either targeted or untargeted, interact with 
the reticuloendothelial system very soon after intravenous injection. This interaction 
promotes uptake in the liver and spleen and limits even very rapid targeting efforts. For the 
first several hours after injection, the CdTe NP are subject to interaction with the 
reticuloendothelial system of the animal but then become refractory to removal. Temporary 
depletion of phagocytic cells can increase targeting efficiency and retention of the CdTe NP 
at the target site. The elimination of CdTe NP from the body is complex, and at least, some 
of the injected NP remain in body tissues for weeks after injection. Long whole-body 
retention times can lead to increased organ toxicity and radiotoxicity.46 Quantum dots (QDs) 
can be used to perform multicolor images with high fluorescent intensity and are of a 
nanosize suitable for lymphatic imaging via direct interstitial injection. Kobayashi et al. 
(2007) showed simultaneous multicolor in vivo wavelength-resolved spectral fluorescence 
lymphangiography using five quantum dots with similar physical sizes but different 
emission spectra. This allows noninvasive and simultaneous visualization of five separate 
lymphatic flows draining and may have implications for predicting the route of cancer 
metastasis into the lymph nodes.47Combination of the multiplexing capabilities of both 
SPECT (with different isotopes) and QDs may be worth exploring in the future for multiple-
event imaging. A few other reports have focused on radiolabeling QDs with PET isotopes 
such as 18F (t1/2: 110 min) and 64Cu.48-50 However, neither incorporation of a targeting 
moiety nor optical imaging was carried out in these studies. Due to the difficulties in 
quantifying the fluorescence signal in vivo and many other technical challenges which 
remain to be solved, in vivo imaging of QDs is so far mostly qualitative or semi-
quantitative.51-53 PET has been routinely used in the clinic for staging and evaluating many 
types of cancer.54 Development of a dual-modality agent containing both a NIR QD and a 
PET isotope will allow for sensitive, accurate assessment of the pharmacokinetics and tumor 
targeting efficacy of NIR QDs by PET, which may greatly facilitate future translation of QDs 
into clinical applications.55 Vascular endothelial growth factor (VEGF)/VEGF receptor 
(VEGFR) signaling pathway plays a pivotal role in regulating tumor angiogenesis.56 Many 
therapeutic agents targeting VEGF or VEGFR are currently in preclinical and clinical 
development.57,58 Since the radiolabeled QDs primarily targeted the tumor vasculature 
rather than the tumor cells, we investigated VEGFR targeting of QDs in a follow-up study.59 
Tumor uptake of 64Cu-labeled DOTA-QD was significantly lower than that of 64Cu-labeled 
DOTA-QD-VEGF. Most importantly, good correlation was also observed between the 
results measured by ex vivo PET and NIRF imaging of excised major organs. In clinical 
settings, optical imaging is relevant for tissues close to the surface of the skin, tissues 
accessible by endoscopy, and during intraoperative visualization.41 Combination of PET and 
optical imaging overcomes the tissue penetration limitation of NIRF imaging and enables 
quantitative in vivo targeted imaging in deep tissue, which will be crucial for future image-
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guided surgery through sensitive, specific, and real-time intra-operative visualization of the 
molecular features of normal and diseased processes. One scenario where a QD-based dual-
modality PET/NIRF agent will be particularly useful is that an initial whole body PET scan 
can be carried out to identify the location of tumor(s), and optical imaging can be 
subsequently used to guide tumor resection.15 
MRI is a non-invasive diagnostic technique based on the interaction of protons (or other 
nuclei) with each other and with surrounding molecules in a tissue of interest.60 Different 
tissues have different relaxation times which can result in endogenous MR contrast. The 
major advantages of MRI over radionuclide-based imaging are the absence of radiation, 
higher spatial resolution (usually sub-millimeter level), and exquisite soft tissue contrast. 
The major disadvantage of MRI is its inherent low sensitivity, which can be partially 
compensated for by working at higher magnetic fields (4.7–14 T in small animal models), 
acquiring data for a much longer time period, and using exogenous contrast agents. IO 
nanoparticles, consisting of a crystalline IO core surrounded by a polymer coating such as 
dextran or PEG, are the most widely used nanoparticle-based MR contrast agents.61 The 
presence of thousands of iron atoms in each particle can give very high T2 relaxivity.62 
Accurate localization of PET probe uptake is very difficult in cases where anatomical 
structures are not identifiable, particularly in the abdomen.63,64 MRI has exquisite soft tissue 
contrast and combination of PET/MR can have many synergistic effects. PET/MR imaging, 
acquired in one measurement, has the potential to become the imaging modality of choice 
for various clinical applications such as neurological studies, certain types of cancer, stroke, 
and the emerging field of stem cell therapy.65 The future of PET/MR scanners will greatly 
benefit from the use of dual-modality PET/MR probes. Recently, an 124I (t1/2: 4.2 days)-
labeled IO nanoparticle was also reported as a dual-modality PET/MR probe for lymph 
node imaging in rats.66 This nanoparticle may be useful in the clinic for accurate localization 
and characterization of lymph nodes, which is critical for cancer staging since the lymphatic 
system is an important route for cancer metastasis.68 
3. Radiation therapy with radiolabeled nanoparticles 
Radiation therapy (radiotherapy) has been quite effective in the treatment of different types 
of cancer and minimizing the risk of local recurrence after surgical removal of the primary 
tumor.76,77 Radiation kills cells largely through the generation of free radicals, which 
deposits a large amount of energy that can cause single- and double-strand breaks in the 
DNA. Generally, tumor cells are less capable of repairing DNA damage than normal cells 
since the tumor cells are more frequently in a sensitive cell-cycle phase, such as mitosis.78,79 
The radiation dose is divided into a number of treatment fractions to allow DNA repair to 
take place within the normal cells and let proliferating tumor cells redistribute through the 
cell cycle and move into more radiosensitive phases. The main goal of radiotherapy is to kill 
tumor cells selectively, without damaging the normal cells.15Radiation therapy utilizes 
radiation energy to induce cell death. By directly delivering external radiation beams to a 
tumor in the patient, external radiation therapy offers a relatively simple and practical 
approach to cause radiation damage in the tumor. Although the intensity, location and 
timing for external radiation can be well controlled and modulated, its main disadvantages 
include: 1) the destruction of normal tissue adjacent to tumors and in the path of the beam; 
2) the need of high radiation doses for penetrating tissues with a large field or volume; 3) 
prolonged treatment with the requirement of daily hospital visits for 5–6 weeks; and 4) the 
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use of only selected radiation sources due to the technical requirements and limitations of 
radiation devices and radiation sources (e.g. high energy x-rays). Therefore, external 
radiation treatment may not be applicable to certain cancers and not effective in the 
improvement of clinical symptoms.68 In contrast to external radiation treatment, systemic 
radiotherapy delivers radiation energy from the radioisotopes that are conjugated to a 
suitable delivery carrier, such as antibodies, liposome emulsions or nanoparticles with 
tumor targeting ligands, and transported to the tumor site as illustrated in Figure 1. 
 
 
 
 
External radiation 
 
 
Systemic radiation 
Fig. 1. External radiation therapy and systemic radiation therapy (Reference 2). 
Since tumor targeted and localized delivery of radiation enhances the treatment effect and 
reduces the toxicity to normal tissue, systemic radiotherapy is considered to be a promising 
approach for personalized oncology. Although systemic radiotherapy presents major 
challenges in the design and production of delivery vehicles, it offers great opportunities for 
the application of novel nanomaterials and nanotechnologies. 
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Although many radioisotopes can be used as radiation sources, only a few have been 
developed and applied in preclinical and in vivo studies. When selecting a candidate for 
experimental and clinical studies, the advantages and disadvantages of radioisotopes 
should be evaluated based on their physical and chemical properties, patient and 
environmental safety, specific requirements for in vivo applications and technical feasibility. 
Table 1 summarizes the physical and radiation properties of therapeutic radioisotopes that 
have been used in previous studies. These radioisotopes can be categorized into three types, 
ie, ǂ, ǃ and auger particles. 
 
Radioisotopes 
Particle(s) 
emitted 
Half-life 
Particle 
energy (keV) 
Maximum 
particle range 
┙-particle   
211At  7.2 hours 6,000 0.08 
225Ac  10 days 6-8,000 0.1 mm 
212Bi  60.6 minutes 6,000 0.09 mm 
213Bi  46 minutes 6,000 <0.1 mm 
223Ra  11.4 days 6-7,000 <0.1 mm 
212Pb  10.6 hours 7,800 <0.1 mm 
149Tb  4.2 hours 400 <0.1 mm 
┚-particle     
131I ,  193 hours 610 2.0 mm 
90Y  64 hours 2,280 12.0 mm 
67Cu ,  62 hours 577 1.8 mm 
186Re ,  91 hours 1,080 5.0 mm 
177Lu ,  161 hours 496 1.5 mm 
64Cu  12.7 hours 1,670 2.0 mm 
Auger-particle     
67Ga Auger,  78.3 hours 90 10 nm 
123I Auger,  13.3 hours 159 10 nm 
125I Auger,  60.5 days 27 10 nm 
Abbreviation: keV, kilo electron volts. 
Table 1. Characteristics of some therapeutic radioisotopes (Reference2) 
3.1 -emitters 
Many radioisotopes emit -particles but most of them decay too quickly to be considered for 
therapeutic use. Only a few -emitters, including actinium-225 (225Ac), astatine-211 (211At), 
bismuth-213 (213Bi) and bismuth-212 (212Bi), have therapeutic potential and have been 
investigated in animal models or humans. ǂ-particle emitterscan eject high energy (4 – 8 
MeV) helium nuclei (i.e. ǂ-particle) which can cause severecytotoxicity, however their 
ejection range is quite short (typically 40 – 80 μm). -particles have linear energy transfer 
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(LET) of 100 keV/µm. LET refers to the average radiation energy deposited in tissue per unit 
length of track (keV/µm). Cell death occurs only when -particles traverse the cell nucleus. 
By virtue of these properties, -particles are highly efficient and specificin treatment of 
microscopic and small-volume tumors, or residual tumors in a variety of cancer types, 
including leukemia, lymphoma, glioma, melanoma, and peritoneal carcinomatosis.76-81 
However, poor radionuclide supply, complicated methodologies for calculating the 
radiation dosimetry and the need for relevant data relating to normal organ toxicity limit the 
applications of -emitter radioisotopes and impede the development of targeted -
emitters.82  
3.2 β-emitters 
ǃ-emitters are the most widely used radioisotopes in cancer therapy. These radioisotopes 
can release electrons which have lower energy and cause lower cytotoxicity than the ǂ-
particle emitters do, but they can travel a much longer distance and kill cells by indirect 
damage to the DNA.15 Commonly used ǃ-emitter radioisotopes are iodine-131 (131I), 
yttrium-90 (90Y); copper-67 (67Cu), rhenium-186 (186Re), lutetium-177 (177Lu), and copper-64 
(64Cu). 131I and 90Y are the most popular candidates since these two isotopes are readily 
available and inexpensive.131I has a long half-life (8 days) and also provides -emissions that 
can be used in imaging for tracking and quantifying the radioisotope in vivo. It can be easily 
attached to tumor targeted antibodies.83,84  131I gets rapidly degraded and has a short 
retention time in the tumor.79 Additionally, the high energy -emission presents some safety 
concerns to patients and the environment. 90Y has fewer environmental radiation restrictions 
than 131I because of its pure ǃ-emitter nature, higher energy and low-range (12 mm), and a 
longer residence time in the tumor, making it more suitable for the irradiation of large 
tumors that require a higher radiation dose and a stable link between radioisotopes and the 
tumor targeting antibody.79 ǃ -particles have lower LET and longer radiation ranges than -
particles. Because of their long radiation range (several millimeters), ǃ-particles can destroy 
tumor cells through the “crossfire effect,” even though the radioimmunoconjugate is not 
directly bound to the cells. Therefore, they are particularly useful in overcoming treatment 
resistance. ǃ-particles are considered to be most suitable for the treatment of bulky or large 
volume tumors.85 
3.3 Auger-emitters 
An auger is a low energy (1.6 keV), and short- range ( 150 nm) electron derived from 
inner-shell electron transitioning. During the decay of these radioisotopes, the vacancy 
formed in the K shell as a consequence of electron capture or internal conversion is rapidly 
filled by electrons dropping in from higher shells, resulting in a cascade of atomic electron 
transitions and emitting a characteristic X-ray photon or an auger. Auger emitters, such as 
gallium-67 (67Ga), iodine-123 (123I) and iodine-125 (125I), have been used for cancer 
radiotherapy. Auger emitters deposit high linear energy transfer (LET) over extremely short 
distances and are therefore most effective when the decay occurs in the nucleus and less so 
when the decay occurs in the cytoplasm. The dimensions of many mammalian cell nucleus 
components, such as chromatin fiber (30-nm), fall in the range of the auger emitter (<150 
nm); therefore, auger emitters are more damaging to these cellular structures. As a result, 
the use of auger emitters has been relatively restricted because of the extreme toxicity of 
such radioisotopes.86Electrons from Auger electron emitters travel the shortest range (< 1 
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μm) and are cytotoxic only when they are very close to the nucleus, thus Auger electron 
emitters are generally not applicable to nanoparticle-based radiotherapy.  
The selection of radioisotopes for cancer therapy should take into account the specific cancer 
types, characteristics of the tumor, toxicity and safety of radioisotopes, availability and 
production of radioisotopes, and the chemistry that is involved in assembling the 
radioisotopes to the delivery carriers. It has been shown that a combination of radioisotopes 
with different energies can be more beneficial than using a single radioisotope. It was 
experimentally found that the combination of a high energy and long tissue range 
radioisotope with a medium energy and shorter tissue range radioisotope is able to destroy 
both large-volume tumors and micrometastases.79 Tumor-targeted nanocarriers have been 
designed to deliver radionuclide payloads in a selective manner to improve the efficacy and 
safety of cancer imaging and therapy.1,73-75 
4. Antibodies conjugated radioisotopes for tumor targeted radiation therapy 
Most of the anticancer drugs are unable to differentiate between cancerous and normal cells, 
leading to systemic toxicity and adverse effects. A simple tumor targeting strategy is the use 
of monoclonal antibodies (mAb) interacting with cancer cell surface markers.87 
Small, high affinity antibody fragments, such as single chain antibodies and affibodies, 
which are expressed as recombinant proteins in prokaryotic cells, are cost effective targeting 
ligand.88 They have been extensively investigated for the delivery of radioisotopes, as 
internal radiation sources. 89–91 This method of using mAbs conjugated with radioisotopes 
for internal or systemic radiation treatment is known as radioimmunotherapy. 
There are several limitations in using antibody conjugated radioisotopes for the delivery of 
radiation therapy. Firstly, mAbs may bind to cell surface markers on normal tissues, causing 
potential systemic toxicity. Secondly, mAbs have only a few sites available for conjugating 
radioisotopes. Therefore, delivery of a large dose of therapeutic radioisotopes may require a 
larger amount of antibodies. Thirdly, the use of mAbs presents potentially unwanted 
immune responses. Additionally, antibodies may be susceptible to protease degradation. 
Attempts are being made to overcome these limitations using nanoparticulate delivery 
systems. 
5. Biocompatible nanoparticles 
Nanoparticles are colloidal materials that can be fabricated with a variety of compositions 
and morphologies using special techniques and chemistries. Nanomaterials currently used 
in biomedical applications include fluorescent CdSe nanoparticles known as quantum dots 
(QDs), photosensitive gold nanoparticles, magnetic nanoparticles, as well as polymeric 
nanoparticles and nanoscale liposomes. Nanoparticles, especially metallic and metal oxide 
nanoparticles, in the “mesoscopic” size range of 5–100 nm in diameter often exhibit unique 
chemical and physical properties that are not possessed by their bulk or molecular 
counterparts.92 For example, QDs made from CdSe exhibit photoluminescence with a 
controllable wavelength ranging from the visible to near infrared depending on their size. 
Colloidal gold nanoparticles exhibit unique surface plasmon resonance (SPR) properties 
derived from the interaction of electromagnetic waves with the electrons in the conduction 
band.93 Magnetic nanoparticles, such as iron III oxide (Fe3O4), are superparamagnetic and 
exhibit high magnetization and yet no residual magnetization in the absence of an externally 
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applied magnetic field.94 Both the chemical properties and reactivity of the nanoparticles are 
controlled by the surface chemistries offered by functionalized polymer coatings or blocks, 
which are also important to the stability and biocompatibility of the nanoparticles, 
interactions between particles, biomolecules and cells, in addition to tissue distributions of 
the nanoparticles. Nanoparticles provide a large surface area and various types of functional 
groups that allow for chemical reactions taking place on the nanoparticle surface and to 
assemble or load bioactive ligands or small molecular agents. 
6. Biocompatibilities and functionalization of nanoparticles 
Metal oxide nanoparticles are coated with polymers to stabilize them  from aggregating and 
precipitating in physiological conditions while maintaining the desired physical properties. 
These polymers improve biocompatibility of metallic nanoparticles by minimizing toxicity 
and modulating interactions between nanoparticles and biomolecules, cells and tissues. 
They alter secretion and biodistribution of  nanoparticles. Coating polymers are 
functionalized with reactive functional groups, such as –COOH, NH2 and –SH, for 
conjugation with tumor targeting ligands. For carrying and delivering therapeutic 
radioisotopes, coating polymers with reactive functional groups allows for covalent cross-
linking or non-covalently incorporating chelates of radioisotopes. There are a variety of 
polymers and their derivatives, such as dextran, polyethylene glycol (PEG), and dendrimer, 
developed for ensuring the biocompatibility and functionalization of nanoparticles.95,96 For 
instance, Zhang and co-workers modified the surface of iron oxide nanoparticles with 
trifluoroethyl ester-terminal-PEG-silane, which was then converted to an amine-terminated 
PEG.97 The terminal amine groups were used for the conjugation of Cy5.5, a near infrared 
(NIR) optical probe, and chlorotoxin, a targeting peptide for glioma tumors. In vitro MRI 
and confocal fluorescence microscopy showed a strong preferential uptake of the 
multimodal nanoparticles by glioma cells compared to the control nanoparticles and 
noncancerous cells. To reduce nonspecific uptake of nanoparticles by normal tissues and 
extend the blood circulation time of nanoparticles to allow particle accumulation at the 
target site, polymer coatings must be specifically designed to meet such applications. The 
physical characteristics of polymer coated nanoparticles affect their in vivo performance. 
Surface morphology, overall particle size and surface charge are all considered important 
factors that determine toxicity and biodistribution. The overall particle size must be small 
enough to evade uptake by reticuloendothelial system (RES) but large enough to avoid renal 
clearance, leaving a window of between 5.5 and 200 nm.98 However, it has also been 
demonstrated that for particles smaller than 40 nm in diameter, both the biodistribution and 
the half-life of nanoparticles are determined by the coating material rather than the mean 
size.99 The surface charge of nanoparticles depends on the nature of the coating material, 
which in turn plays an important role in determining blood half-life. Nanoparticles with 
strong positive or negative charge tend to bind to cells. 100,101 Thus, nanoparticles with a 
neutral surface charge are recommended to extend circulation times. Nanoparticles with 
neutral surfaces resist protein binding and provide steric hindrance for preventing 
aggregation after in vivo administration.98 New coating materials composed of zwitterionic 
polymers have been developed to provide a biocompatible surface with both positive and 
negative charges, which exhibit high resistance to nonspecific protein adsorption and 
uptake by macrophages in liver and spleen.102-114 Chen and colleagues developed an 
antibiofouling copolymer PEO-b-PMPS for coating nanocrystals.115 This new copolymer 
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made hydrophobic iron oxide nanoparticles mono-disperse in physiological conditions with 
great stability. This amphiphilic blocked coating polymer can be functionalized with 
reactive amine groups on the particle surface, making it readily available for the conjugation 
of tumor targeting ligands and therapeutic agents such as radioisotope chelates. These 
composite nanoparticles showed a reduced nonspecific uptake. 
7. Advantages of nanoparticulate drug delivery system 
Radioisotopes undergo rapid elimination due to their widespread distributions into normal 
organs and tissues. One common solution to this problem is to administer large quantity of 
radioisotope, which is not cost effective and often results in undesirable toxicity. 
Nanoparticles with proper biocompatible polymer coatings provide better platforms for 
carrying radioisotopes and subsequently delivering the agents to the tumor. There are 
several advantages of using nanoparticles to deliver  therapeutic radioisotopes: 
i. Nanoparticles have prolonged blood retention time, ranging from 30 minutes to 24 
hours, depending on the morphology and size of the particle, coating materials and 
compositions of nanoparticle conjugates.  
ii. Nanoparticulate carriers used for targeting cancer cells exhibit high tumor retention 
time and thus enhance the concentration of therapeutic agents. 
iii. Nanoparticles have high loading capacity, they can even carry more than one type of 
radioisotope.  
iv. Internalization of receptor targeted nanoparticles leads to the uptake of large amounts 
of radioisotopes into the target cells, resulting in effective killing of tumor cells with a 
relatively low level of receptor-expression.  
v. The unique chemical and physical properties of nanoparticles, such as magnetization 
and photosensitizing provide additional capabilities and functions for improving 
delivery of the radioisotopes and monitoring the response to radiotherapy.  
With the controlled formulation and optimized drug carrying strategies, nanoparticle 
platforms may offer appropriate pharmacokinetics for optimal delivery of radioisotopes for 
cancer treatment. Radioisotopes can be conjugated on to hydrophilic functional groups 
present on the surface of micelles for better transport.106Nanoparticulate drug delivery 
system often possess multi-functional capacity which enables it to load multiple moieties 
like targeting ligands and therapeutic agents. This is of immense importance to tumor 
targeted delivery of radioisotopes in vivo. It has been reported that nanoparticles consisting 
of streptavidin that linked three biotinylated components: the antiHer2 antibody 
trastuzumab, the tat peptide and the 111In-labeled antiRIa messenger RNA antisense 
morpholino (MORF) oligomer, produce significant radiation-induced antisense mediated 
cytotoxicity of tumor cells in vitro.107 
8. Strategies for targeting nanoparticles to cancer 
Principally, two mechanisms are used for targeting nanoparticles to tumors, passive and active 
targeting. In passive targeting, nanoparticles reach the tumor through highly permeable tumor 
vasculature. They get accumulated in the tumor and subsequently remain their due to its lack 
of lymphatic drainage. In active targeting, nanoparticles are engineered to target specific 
biomarker molecules that are unique and over populated in a tumor or cancer cell surface. 
Differences in the expression of cellular receptors between normal and tumor cells provides an 
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opportunity for targeting nanoparticles to cancer cells. Active targeting nanoparticles carrying 
radioisotopes to tumors are the current research focus and the subject of intensive 
investigations. The surface coating polymer of nanoparticles is conjugated to ligands like 
antibodies, peptides and small molecules targeting the receptors highly expressed on tumor 
cells. Extensive reviews and discussions on the mechanisms of targeting nanoparticles to 
tumors have been published.3,108-109 In vivo tumor targeting have been achieved using folic 
acid modified dendrimers,111 synthetic small-molecule modified iron oxide nanoparticles,112 
PEGylated arginine-glycine-aspartic acid peptide modified carbon nanotubes113 and 
PEGylated single chain variable fragment antibody modified gold nanoparticles.93 Tumor 
targeted nanoparticles are believed to be a promising platform for nanobiotechnology. 
Antibodies have been extensively studied as tumor targeting ligand for magnetic or 
photosensitive nanoparticles in the area of cancer imaging. Conjugates of nanoparticles and 
antibodies were found to retain the properties of both the antibody and the nanoparticle. 
Herceptin, a well-known antibody against HER2/neu receptors which are over-expressed in 
breast cancer cells when conjugated with magnetic iron oxide nanoparticles showed in vivo 
cancer targeting and imaging of HER2/neu with a high sensitivity. The smallest parts of the 
antibody, the so called ScFv, are among the frequently used ligands. Nanoparticles 
conjugated with mAb fragments have increased circulation times in the blood compared to 
nanoparticles conjugated with whole mAbs. Because mAb fragments lack the Fc domains 
which binds to Fc receptors on phagocytic cells.114 
Besides mAbs and antibody fragments, small molecule ligands can be readily obtained from 
chemical synthesis in a large quantity. Small peptide ligands, such as Arg-Gly-Asp (RGD) 
has high affinity for tumor integrins vǃ3 or vǃ5 in its conformationally constrained cyclic 
form than its linear form, have been extensively investigated for their applications in 
delivering tumor targeted nanoparticles carrying imaging and therapeutic agents. This 
increases the probability of RGD-targeted nanoparticles to act on tumor endothelial cells 
and produce anti-angiogenesis effect.115,116 The folate receptor (FR) is an attractive molecular 
target for tumor targeting because it is over expressed by most of tumor cells like ovarian, 
colorectal, breast, nasopharyngeal carcinomas and has limited expression in normal 
tissues.117,118FR-mediated tumor delivery of drugs, gene products, radionuclides and 
nanoparticles for imaging have been reported.119-121 Folic acid, attached to 
polyethyleneglycol-derivatized, distearyl-phosphatidylethanolamine, was used to target in 
vitro liposomes to folate receptor (FR)-overexpressing tumor cells. Confocal fluorescence 
microscopic observations demonstrated binding and subsequent internalization of 
rhodamine-labeled liposomes by a high FR-expressing, murine lung carcinoma line (M109-
HiFR cells), with inhibition by free folic acid. Additional experiments tracking doxorubicin 
(DOX) fluorescence with DOX-loaded, folate-targeted liposomes (FTLs) indicate that 
liposomal DOX is rapidly internalized, released in the cytoplasmic compartment, and, 
shortly thereafter, detected in the nucleus, the entire process lasting 1-2 h. FR-mediated cell 
uptake of targeted liposomal DOX into a multidrug-resistant subline of M109-HiFR cells 
(M109R-HiFR) was unaffected by P-glycoprotein-mediated drug efflux.122 
9. Radioisotope loaded nanoparticles for tumor targeting 
Radioisotopes are very powerful agents in diagnosis and treatment of solid tumors.130-131 
However they lack tumor selectivity, damage surrounding normal tissues and organs, 
which results severe toxicity that often outweighs their anti-tumor effects. Many researchers 
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have focused on the direct administration of radioisotopes into the tumor site. This method 
appears to be very effective, but failed due to rapid clearance from the injected tumor site. 
There is a strong indication that radioisotope carriers can improve the efficiency of 
intratumoral administration.126,127 Suzuki et al. described the biodistribution and kinetics of 
the Holmium 166–chitosan complex in rats and mice. They suggested that chitosan 
prolonged the retention time of Holmium 166 in the tumor site.126 Nakajo et al. also 
designed a 131I-labeled lipiodol for the treatment of liver cancer patients. They determined 
that the radioactive concentration in blood after 131I-lipiodol administration could be 
maintained at levels as low as 10 × 10−4% injected dose (ID)/mL for 8 days.127 Stimuli-
sensitive polymeric nano-carriers are another potential candidate for intratumoral 
radioisotope administration. They are readily administered due to their favorable 
biocompatibility, small size, and low viscosity. Alterations in their properties (hydrophilic to 
hydrophobic) help them accumulate in tumor sites, which results in prolongation of 
radioisotope retention time.128 Very few studies have been conducted using polymeric 
nanoparticles labeled radioisotopes for anti-tumor treatment.129 Conventional polymeric 
nanoparticles from amphiphilic block or random copolymers possess insufficient functional 
groups for radioisotope labeling, which results in lower labeling efficiency. Whereas, self 
assembled nanoparticles from polysaccharide derivatives facilitate the tagging process, as a 
consequence of their abundant functional groups, which enable the direct labeling of 
radioisotopes. Park et al. utilized ionic strength (IS)-sensitivity in the development of new 
radioisotope carriers for intratumoral administration. A polysaccharide derivative, pullulan 
acetate nanoparticle (PAN)was prepared via dialysis. The PAN had a spherical shape with 
size range of 50–130 nm and a low critical aggregation concentration (CAC) (<8_g/mL). 
With increases in the IS of the dialysis media, the CAC of PAN was reduced gradually and 
the rigidity of the hydrophobic core in PAN was increased. This suggests that the property 
of PAN was altered more hydrophobically at high IS values. PAN evidenced a high degree 
of 99mTechnetium (99mTc) labeling efficiency (approximately 98%). The percentage retention 
rate (%RR) of the 99mTc-labeled PAN was significantly longer than that of the free 99mTc (p < 
0.05), due largely to PAN’s IS-sensitivity. Thus, PAN may constitute a new approach to the 
achievement of maximal radioisotope efficiency with regard to intratumoral 
administration.122 Noninvasive, focused hyperthermia can be achieved by using an 
externally applied alternating magnetic field (AMF) if effective concentrations of 
nanoparticles can be delivered to the target cancer cells. Monoclonal antibodies or peptides, 
linked to magnetic iron oxide nanoparticles (NP), represent a promising strategy to target 
cancer cells. A new radioconjugate NP ((111)In-DOTA-di-scFv-NP), using recombinantly 
generated antibody fragments, di-scFv-c, for the imaging and therapy of anti-MUC-1-
expressing cancers was developed by Natarajan et al.130 
10. Future implications 
With the advent of nanotechnology, researchers world over are interested in designing a 
magic bullet which would detect the malignant tissue and destroy it. Radionuclides can be 
targeted to malignant tissue by coupling them to antibodies or their parts. These 
radioimmunoconjugates are being developed to meet the challenges facing cancer detection 
and therapy today and in the future. Several radiolabeled multifunctional and 
multimodality nanoparticles have been effectively demonstrated in detecting and treating 
cancer in animal models. However, further preclinical and clinical efficacy and toxicity 
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studies are required to translate these advanced technologies to the health care of cancer 
patients. 
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